Zanubrutinib, BGB-11417, BGB-11417
BGB-11417-203
Phase 2 small_molecule active
Quick answer
Zanubrutinib, BGB-11417, BGB-11417 for previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia is a Phase 2 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active